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ABSTRACT
TheendonucleaseP2AinitiatestheDNAreplicationof
the bacteriophage P2by making acovalentbond with
its own phosphate backbone. This enzyme has now
been exploited as a new in vitro display tool for anti-
bodyfragments.Wehaveconstructedgeneticfusions
of P2A with single-chain antibodies (scFvs). Linear
DNA of these fusion proteins were processed in an
in vitro coupled transcription–translation mixture of
Escherichia coli S30 lysate. Complexes of scFv–P2A
fusion proteins covalently bound to their own DNA
were isolated after panning on immobilized antigen,
and the enriched DNAs were recovered by PCR and
prepared for the subsequent cycles of panning. We
have demonstrated the enrichment of scFvs from
spiked libraries and the specific selection of different
anti-tetanus toxoid scFvs from a V-gene library with
50 million different members prepared from human
lymphocytes. This covalent antibody display techno-
logyoffersacompleteinvitroselectionsystembased
exclusively on DNA–protein complexes.
INTRODUCTION
Antibodies are protein ligands with awide range of biomedical
applications. They have been displayed and evolved success-
fully by different in vivo-o rin vitro-based selection methods
using, for example, phage particles, yeast or bacteria cells
(1–3). One limitation of the in vivo selection systems is the
library size that could be generated. A large library is con-
sidered to be important to obtain high-afﬁnity ligands. How-
ever, the efﬁciency of transfer of DNA into cells often limits
the library size to 10
9–10
10 members (3–6). In vitro-based
antibody selection methods such as ribosome display or
mRNA display have proven to be successful in the construc-
tion and selection of libraries with a high diversity and com-
plexities (potentially up to 10
14 different members) (5–9).
Bothtechnologiesare based onan initial selection ofstabilized
mRNA–protein complexes (4–10).
All the present antibody selection systems only indirectly
link phenotype and genotype via cell membranes, phage–
protein coat, mRNA–ribosomes, protein–puromycin–mRNA
complexes or water/oil emulsions (1–3,7,8,11,12). In nature,
however, there is a protein from the bacteriophage P2 that
offers a direct DNA–antibody selection system. This phage
replicates by attaching its early gene product P2A to its own
DNA. The ﬁrst genetic evidence of the cis-activity in vivo was
obtained when the wild-type P2 phage did not complement
mutations in P2A (13). P2A initiates the rolling circle replica-
tion of the P2 phage in vivo. Its catalytic tyrosine residue
(Y454) makes a single-stranded-speciﬁc nick at the viral ori-
gin of replication, located at base pair 1860 inside the 2.3 kb
P2A gene, and forms a covalent bond with the 50-phosphate
group of the coding strand (14–16) (Figure 1a).
A single chain antibody (scFv) can be genetically fused to
the P2A protein creating the smallest imaginable antibody
selection particle: a protein and its gene (Figure 1b). Covalent
antibody display (CAD) exploits the demonstrated in vivo cis-
activity of P2A in an in vitro selection system: a fusion protein
of P2A and an scFv antibody binds to the same molecule of
DNA from which it has been expressed. Following in vitro
coupled transcription and translation, the P2A protein makes
a covalent link between scFv genotype and scFv phenotype,
by producing a stable protein–DNA complex (14–17). P2A
may thus be exploited to select scFvs from a library by using
onlyinvitro methods.Theseantibody–DNAcomplexes canbe
isolated with standard afﬁnity selection strategies. Speciﬁc
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Figure1.(a)TheendonucleaseP2A(761residues,86.3kDa)makesasingle-strandedsite-specificnickatOriofreplication(...CCTCGG,*),locatedinsideitsown
geneatposition1860,andbecomescovalentlyattached(viaY454)tothe50 phosphateofitsownDNA(14–16).(b)CADistheexploitationofP2Atoselectantibodies
orantibodyfragmentsgeneticallyfusedtoit.Inprokaryotes,thetranscriptionandtranslationarecoupled,andthestartoftranslationnormallytakesplacebeforethe
transcription is finished (17). The figure is a model of the complex formation among DNA, RNA polymerase, ribosomes, mRNA and nascent P2A–scFv fusion
proteins (colours match the gene products). The P2A protein part of the P2A–scFv fusion protein indirectly attaches the genotype of the scFv covalently to its
phenotype. (L = linker). (c) Selection cycle for CAD. An scFv repertoire is assembled with the P2A gene using PCR methods and fresh P2A and tac-promoter (1).
Protein–DNAcomplexesarebeingproducedinaninvitroE.coliS30coupledtranscription–translationmixture(2)andselectedontheimmobilizedtarget(3and4).
Retained members are eluted and DNA for the next cycle is prepared using PCR (5). Figures are not drawn to scale.
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ampliﬁcation (Figure 1c).
In the present study, we have demonstrated the suitability
of P2A for speciﬁc selection of scFvs. Fusion proteins of
scFv–P2A were expressed and DNA–antibody complexes
were speciﬁcally recovered on antigen-coated solid phase.
In addition, we have applied this technology to select antibod-
ies from spiked and medium complex libraries. We propose
that CAD can be exploited as a complete and independent
in vitro antibody display tool for afﬁnity selections.
MATERIALS AND METHODS
PCR cloning and assembly
The scFvs anti-phOx [phOx, 4-ethoxymethylene-2-phenyl-2-
oxazoline-5-one (18); anti-phOx (19)] and anti-DOB [DOB,
2,5-dimethoxy-4-bromo-amphetamine (20); in house made
anti-DOB (unpublished data), speciﬁc against DOB] were
fused to either the N-terminal or C-terminal position of
P2A with standard PCR cloning techniques, attaching a
GSGSGS linker containing suitable ﬂanking restriction sites
(EcoRI, NotI, XhoI or NcoI) and two stop codons at the 30 end
(Figure 2). A vector tacP2aHa (5926 bp) containing the P2A–
HA gene under the control of a tac promoter was supplied by
Isogenica Ltd. Pfu Turbo DNA polymerase (Stratagene) was
applied for generating GS-linker-scFv products for cloning.
The PCR mixture was composed of 200 mM dNTP mixture,
30 ng vector DNA-template, 0.6 mM primers GsDOB3F
(aaattaaaactcgagggttctggctccggttccatggcggaagtgcagctggtgc;
XhoI and NcoI sites are underlined and GSGSGS sequence is
in italics)/EcoRIPhog (tttttttgaattctatcagtgatggtgatggtgatgtg-
agtttagg; EcoRI site is underlined and HHHHHH sequence is
in italics) or GsPhOxF (aaattaaaactcgagggttctggctccggttcc-
atggcccaggtgcagctggtgc; XhoI and NcoI sites are underlined
and GSGSGS sequence is in italics)/EcoRIPhog in the Pfu
reaction buffer. Initial denaturation was at 94 C for 5 min
followed by 30 cycles at 94 C (1 min), 63 C (1 min) and
72 C (2 min 30 s) in an Eppendorf Mastercycler Gradient
PCR machine. The ﬁnal elongation step was at 72 C for
5 min. The GS-linker-P2A for cloning scFvs at the 50 of
P2A was produced by Pwo Polymerase (Roche, Norway) at
an annealing temperature of 65 C [primers: GsP2af (aaatt-
aaatgcggccgcgggttctggctccggttccatggccgttaaagcctccggg; NotI
and NcoI sites are underlined and GSGSGS sequence is in
italics)/Lanrb (gtggataaccgtattaccgcc)]. The Pwo PCR pro-
gramme was as follows: 94 C for 2 min, with initial 10 cycles
at 94 C (30 s), 65 C (1 min) and 72 C (2 min), then 20 cycles
at 94 C (30 s), 65 C (1 min) and 72 C (2 min) increasing the
extension time with 5 s per cycle, and with a ﬁnal elongation
step at 72 C for 7 min. To clone small scFv libraries (scFv)n
into the scFv–GSGSGS–P2Avector via NcoI/NotIsites, itwas
necessary to delete the second NcoI site at the beginning of
P2A (Figure 2). This site was removed with the primers
GSP2Afnew (aaattaaatgcggccgcgggttctggctccggttctatggccgtt-
aaagcctccggg; NotI site is underlined, GSGSGS sequence is in
italics) and Lanrb and Pwo polymerase as described previously.
Standard methods were applied for heat transformation of
Figure 2. PrimerandrestrictionsitesforrescuePCRandassemblyofDNAfornextroundsofCAD.Top:P2A–HAconstruct;middle:P2A–scFv;andbottom:scFv–
P2A.HA,haemagglutininpeptideepitopeofhumaninfluenzavirus(YPYDVPDYA);c-Myc,myconcogeneepitope(EQKLISEEDL);His6,hexahistidinesequence
(HHHHHH).
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a or Origami cells (Novagen). The transformed cells were
grown in SOC medium at 37 C for 1 h shaking at 260
r.p.m. and plated on SOC/ampicillin (100 mg/ml) agar dishes
for 15–20 h at 37 C.
Input linear DNA of P2A–scFv and scFv–P2A clones for
coupled transcription and translation were made by either
Pwo or Tgo DNA polymerase (Roche, Norway) with a
hot-start technique. Preparations of plasmids (ligation
mixtures or minipreps; 0.5 mg) were used as template for
PCR, and the primers P2AampF (gcttcagtaagccagatgctac,
30 pmol) and LAMPB (tacaccgaactgagata cctac, 30 pmol)
were chosen for producing the  4 kb DNA fragment
comprising tac-promoter, scFv and P2A (Figure 2). The PCR
programme for Tgo DNA polymerase was as follows: 94 C
(2 min), cycling 30 times at 94 C (30 s), 65 C (1 min) and
72 C(3min)followedbya7minincubationat72 C.Thelinear
DNAfragmentswereseparatedonagarosegelandpuriﬁedwith
Qiaquick gel extraction kit (Qiagen). Extra washing steps were
necessary in order to remove all the salt components inhibiting
transcription and translation. The products were adjusted to a
high-concentrationsample(1–3mg/ml)byalcoholprecipitation
and applied in coupled transcription and translation.
In vitro transcription-translation
Reaction buffer (2.5·) and E.coli [strain SL-119, (21)] S30
extract (22) with 1 mM DTT (Sigma) were applied. For a 50 ml
reaction in an Eppendorf tube, the following components were
assembled on ice: S30 2.5· reaction buffer (20 ml), E.coli S30
extract (15 ml),  1m ML-methionine (Sigma), 1 mM protein
disulﬁde isomerase (PDI; Sigma), 40 U RNasin (Promega),
nuclease-free water, 0.1% BSA and DNA (1–2.5 mg). Gener-
ally, 5–10 mg of DNA was added for each round of selection.
Transcription and translation reaction was started by adding
DNA (1–5 mg per 50 ml reaction) and processed for 60 min at
30 C. After 40 min of incubation, 2 mM of oxidized and
reduced glutathione were added. The reaction was stopped
by diluting the mixture in ice-cold panning buffer and incu-
bated with an immobilized target. The transcription and trans-
lation extract from Promega (E.coli S30 extract for linear
templates) was also applied, but it contains an excess of
DTT, which inhibits the folding of antibodies.
Affinity selections
Dynabeads M-280 Tosylactivated (Dynal Biotech, Oslo,
Norway) were coated with anti-haemagglutinin (anti-HA),
or with the antigens phOx–BSA (18) or DOB–BSA (20) (6 mg
antibody or 20mg hapten–BSA conjugate per mg beads; 20 mg
beads/ml) in 0.1 M sodium carbonate, pH 9.6 at 37 C for 20 h
on an Eppendorf thermomixer at 1200 r.p.m. Then, they were
washed three times in phosphate-buffered saline (PBS), pH7.4
with 0.1% BSA at 20 C and blocked for another 20 h at 20 C
(1200 r.p.m.) in 0.3 M Tris–HCl, pH 8.8 with 0.1% BSA.
Finally, they were washed in PBS, pH 7.4 and stored at a
concentration of 20 mg beads per ml. For the E7 scFv, an
scFv speciﬁc for an outer membrane epitope of Neisseria
meningitidis (E7), the outer membrane vesicles (OMV) made
from the bacteria, were applied as antigen (23). Immuno tubes
(Maxisorp, Nunc, Denmark) were coated with antigens in PBS
(pH 7.4) overnight at 20 C on a blood mixer. The afﬁnity
matrices were pre-incubated with panning buffer SuperBlock
(Pierce) added  0.2 mg/ml herring sperm DNA (Sigma),
0.25% (w/v) heparin and 1% Tween-20 (6,24,25) for 1–2 h
at 20 C on a blood mixer, and then rinsed three times in PBS
before panning mixture was added.
DNA–protein complexes were captured by ﬁrst diluting the
transcription and translation mixture into panning buffer, then
incubating on an afﬁnity coated matrix for 2–4 h rotation at
4 Co ra t2 0  C on a blood mixer. The enriched complexes
werethoroughlywashed inPBSwith0.1%Tween-20,panning
buffer (including an incubation step at 20 C for 30 min) and
in PBS.
The DNA was eluted using proteinase K (50 mg/ml; Sigma)
in TE buffer, pH 8.0 for 45 min at 50 C (26) and ethanol
precipitated in seeDNA (Amersham Pharmacia Biotech).
PCR-rescue, detection of P2A–scFv fusions and
processing scFv clones
If the P2A–scFv fusions have been expressed and puriﬁed,
the enriched DNA of the P2A–scFv construct can be identiﬁed
and ampliﬁed by PCR. The seeDNA precipitated DNA was
dissolvedin10mlofnuclease-freesterileMQ-waterand1–5ml
was used for each PCR-screen. If the input DNA in the tran-
scription and translation mixture was made by PCR, it was not
possible to use the same primers P2AampF and LAMPB in the
PCR mixture as was done for producing it (Figure 2). This was
probably due to the partial degradation of DNA after incuba-
tion. However, by using primer combinations NcoDOBF-
(atggcggaagtgcagctggtg)/NotDOBB(gccgcgaagacagatggtgc),
NcoPhOxF(atggcccaggtgcagctggtgc)/NotPhOxB (gccgca-
cctaggacggtgacc) or scFvseqF (cctgttgacaattaatcatggctcg)/
scFvseqB (cctgcggcaaatgctgacgg) (Figure 2), they generated
products comprising just the scFv gene and short ﬂanking
regions ( 0.8–1 kb). For primer combinations NcoDOBF/
NotDOBB and NcoPhOxF/NotPhOxB, an annealing temper-
ature at 68 C was chosen, and 55 C for scFvseqF/scFvseqB.
For detection purposes, DynaZyme II DNA polymerase
(Finnzymes, Finland) was used, and for ampliﬁcation of new
products for next round of selection, Pwo polymerase (Roche)
was chosen.
The recovered and ampliﬁed scFv DNA from each round of
CAD was either cloned into an assay expression vector
pHOG21 (having a lac promoter and c-myc/His6-tags) (27)
or assembled with tac promoter and P2A gene using restric-
tion/ligation methods into vector tacP2aHa (NcoI/NotI sites;
Figure 2). DNA for the next round of transcription and trans-
lation was generated by PCR using ligation mixture as
mentioned above. For the expression of soluble scFvs in 96
deep-well plates, the pHOG21 expression vector constructs
were transformed into XL-1 Blue cells and induced in
Luria–Bertani (LB) medium containing 100 mg/ml of ampi-
cillin (A) with 100 mM isopropyl-b-D-thiogalactopyranoside
(IPTG) at 30 C and shaken for 16 h. The expressed scFvs were
detected using enzyme-linked immunosorbent assay (ELISA),
or were assayed as described below.
SDS–PAGE, western blotting and enhanced
chemiluminescence (ECL) detection
The samples, added SDS-sample buffer with 2-mercapto-
ethanol, were separated on a 12.5% SDS–PAGE criterion
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membranes, washed (PBS), blocked with Blotto (1% dry milk
inPBS),andincubatedinanti-c-Myc(diluted1:5000inBlotto;
Invitrogen)oranti-HA(1:2000inBlotto;Roche)solutions.The
membrane was washed (PBS with 0.1% Tween-20) and incu-
bated with detection antibody [rabbit anti-mouse-horseradish
peroxidase (HRP); DAKO, Denmark]. The HRP activity on
membrane was visualized in ECL-western blotting reagents
RPN 2106, Hyperﬁlm ECL (both Amersham Pharmacia
Biotech) and a ﬁlm developer.
ELISA and filter screening
Maxisorp 96-well plates (Nunc, Denmark) were coated with
antigen, and expressed scFvs were detected via their c-Myc
tags using antibodies/enzymes as described above. 3,30,5,50-
Tetramethylbenzidene (TMB) was used as a substrate. Filter
screening of 3040 bacterial colonies was performed as
described previously (28). To prepare target ﬁlters (0.45 mm
pore size cellulose nitrate; Schleicher & Schuell Protan BA
85), these were cut to 22 · 7c m
2 and coated with 10 ml of
phOx BSA or DOB BSA at 0.1 mg/ml. Generally, clones were
high-density gridded with a Qpix robot (Genetix, New Milton,
UK) on a BSA-coated ﬁlter surfacing a 22 · 22 cm
2 LB
agar bioassay plate containing 30 mg/ml of tetracycline (T),
100 mg/ml of ampicillin (A) and 0.1 M glucose (G), and grown
for 16 h at 37 C. Then, the BSA ﬁlter with clones was lifted on
top of a sandwich with an antigen-coated ﬁlter in the middle
and fresh LB agar plate with 100 mM IPTG and A at the
bottom, and induced for 16 h at 30 C. The active scFvs
will leak from the periplasm of the colonies to the antigen-
coated ﬁlter underneath. This ﬁlter was developed like a
western membrane as described above.
RESULTS AND DISCUSSION
Constructing a basic scFv–P2A model system
The A protein of the P2 phage can be used as a potential
antibody display tool (Figure 1b and c). To test its suitability,
we chose two well-characterized scFvs against the haptens:
phOx (18) and DOB (20). The scFvs were genetically fused to
P2A at two different positions connected by a (GS)3-linker
and expressed from a tac-promoter. The scFv N-terminal to
P2A with an HA-tag: tacPO-scFv-(GS)3-P2A-HA and scFv
C-terminal to P2A with c-Myc tag: tacPO-P2A-(GS)3-scFv-
cmyc-His6 were constructed (Figure 2). The fusion proteins
and P2A–HA alone were translated in a standard E.coli S30
extract for linear templates (Promega) and sharp bands corre-
sponding to the  90 kDa P2A–HA and the  110 kDa P2A–
scFv proteins were clearly visible, showing efﬁcient in vitro
expression (Figure 3a). Estimating the yield of protein, the
sensitivity of ECL (10
 11 M) indicated a protein band ( 1 ng)
where the input of DNA was 1 mg (Figure 3a). This suggests
that  3% of input DNA produces proteins, which would
require around 30–40 copies of each scFv to be present in
the library to ensure isolation of any unique scFv members.
Antibodies are normally functionally folded in oxidizing or
slightly reducing environments (6,24). To allow RNA poly-
merase activity, which requires a reducing environment, a
specially made transcription and translation mixture was
prepared (see Materials and Methods). Immediately after
transcription and translation, the protein–DNA complexes
were enriched onto target antigen-coated beads, eluted and
detected by PCR.
The display of functional scFv was evaluated at both the
N- and C-terminus of P2A. Figure 3b shows the recovery of
rescued DNA for N- and C-terminal position of anti-phOx
scFv relative to P2A. For the N-terminal position (scFv–
P2A), there was more DNA associated with phOx–BSA
than BSA beads (target PCR signal > background PCR signal).
This illustrates that the DNA enrichment was well correlated
with antibody activity. Similar results were also obtained for
the anti-DOB fusion proteins (data not shown). In contrast, the
C-terminal fusions (P2A–scFv) showed no speciﬁc enrich-
ment. It is possible that the linker length was too short to
accommodate proper folding and functionality of these
fusions, or they were structurally destabilized. Premature
Figure 3. (a) Western/ECL identification of P2A-HA (lane 1) and P2A-anti-
DOB3-c-Myc(lane2)proteinsexpressedin acoupledtranscription-translation
mixture (Promega E.coli S30 extract for linear templates). The proteins were
separated on 12.5% criterion polyacrylamide gel (Bio-Rad), blotted onto
nitrocellulose membrane and detected by anti-c-Myc/anti-HA and rabbit
anti-mouse IgG-HRP/ECL. (b) Agarose gel of rescue PCR of DNA from
anti-phOx-P2A (left panel) or P2A-anti-phOx (rightpanel) protein–DNA com-
plexes selected onto target T (phOx–BSA-coated Dynabeads) or negative con-
trol NC (BSA-coated Dynabeads). The protein–DNA complexes were
generated in E.coli S30 lysate added 1 mM PDI and 1 mM DTT. They were
eluted with proteinase K digestion, alcohol precipitated and detected by PCR.
(c) Agarose gel of rescue PCR of DNA from scFv(E7)–P2A protein–DNA
complexes selected on N.meningitidis outer membrane vesicles (T) or superb-
lock(Pierce,NC).TheeffectofRNase(Promega)treatingsamplesimmediately
after transcription–translation (at 30 C, 10 U) or adding 0.1% BSA during
transcription and translation. The DNA bands from no additions/
post-treatments are also shown (0).
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DNA before scFv is synthesized. This may occur more fre-
quently if the scFv is at the C-terminal end of P2A rather than
at the N-terminal end.
Different additives improve the functionality of
covalent antibody display
Adjusting the redox potential of the transcription and transla-
tion mixture generated active fusion proteins associated with
DNA, and adding BSA increased the yield of DNA recovered
by PCR and improved the signal-to-noise ratio relative to no
addition (Figure 3c). BSA may stabilize enzymes and compo-
nentsinthetranscriptionandtranslationmixtureduringinvitro
synthesis, even though BSA also contributes to a stronger
unspeciﬁc adsorption of DNA (Figure 3c). Furthermore, the
samples were treated with RNase after the protein–DNA com-
plexes were formed (Figure 3c). A similar pre-treatment has
been applied for ribosome display, using DNase to remove
DNA (29). RNase increased the signal-to-noise ratio conﬁrm-
ing that mRNA is not involved during selection (as for ribo-
some display). The enriched active species therefore consist of
pure DNA–protein complexes. In addition, the coupled tran-
scription and translation mixture of an anti-phOx-P2A-HA
DNA construct (Figure 2, bottom) was incubated in 6.3 M
urea before it was diluted in panning buffer and enriched on
anti-HA coated tubes. Still, this harsh treatment made it pos-
sible to speciﬁcally enrich its DNA on anti-HA-coated tubes
(data not shown), and thus did not release the anti-phOx-P2A-
HA protein from its mother DNA. This again conﬁrms that the
anti-phOx-P2A-HA protein is covalently bound to DNA as
shown previously for P2A–HA proteins (13–16).
Enrichment experiments
To demonstrate the recovery of speciﬁc antibody DNA–
protein complexes from a complex mixture, speciﬁc enrich-
mentexperimentswereperformed.Inapopulationwherethere
is only one copy of a speciﬁc P2A-scFv gene among, e.g. 10
7
other different non-active P2A-scFv genes, the cis-activity is
related to the probability of recovering the speciﬁc P2A gene
product binding to its own mother DNA. If the P2A protein
only ﬁnds it own mother DNA molecule, a direct enrichment
of P2A protein–DNA complexes is productive. However, all
selection systems contain a certain amount of noise (non-
relevant gene products) raising the threshold required to detect
rare binders from a large diverse library early in the selection
process (round 1–2). If there were no cis-activity, the amount
of randomness involved would possibly block the enrichment
of the speciﬁc gene and gene product, even after 10–20 cycles.
On the other hand, an early enrichment of active library mem-
bers from a very diverse mixture should demonstrate that there
is a cis-directed selection.
An scFv antibody library from human lymphocytes (PBL)
was constructed by RT–PCR using IGHV-D-J, IGKV-J and
IGLV-J genes. The library having a diversity of n = 5.0 · 10
7
different clones was cloned as an N-terminal fusion to P2A,
(scFv)n–P2A.D N Ao fanti-phOx–P2A or anti-DOB–P2A
fusions were spiked into the library at a ratio of 1:25000
(anti-phOx) and 1:1000 and 1:100000 (anti-DOB) and
subjected to a complete covalent display selection cycle
(Figure 1c). Two spiking strategies were employed. For the
selection of anti-DOB scFvs spiked into the (scFv)n–P2A
library at a ratio of 1:10
3, 4.8 ng of anti-DOB–P2A
DNA (1.1 · 10
9 molecules) and 5 mg (1.1 · 10
12 molecules)
of library DNA were used. Lowering the same spiking ratio to
1:10
5,4 8p go fanti-DOB–P2A (1.1 · 10
7 DNA molecules)
was added into 5 mg (1.1 · 10
12 DNA molecules) of library
DNA. For the selection of anti-phOx, 400 pg of anti-phOx–
P2A DNA was spiked into 10 mgo f(scFv)n–P2A library
(1:25000). The recovered DNA from each round was
analysed using ﬁlter screen as shown for anti-phOx in
Figure 4a. As expected, there were no positive candidates
before the selection of 3040 clones in the unselected
library. However, after round 1–3 (R1–R3) of CAD, the num-
ber of enriched clones increased from 6 (R1), 49 (R2) to 82
clones (R3). The enrichment after each round is also illustrated
in Figure 4b. The clones were MvaI digested (30) and their
restriction fragment length polymorphism (RFLP) patterns
conﬁrmed their anti-phOx–P2A identity. Enrichment was
also seen after analysing 1:1000 and 1:100000 spiking of
anti-DOB–P2A into the same library, respectively. After R1
of CAD 28 positive anti-DOB–P2A clones (1:10
3 spiking)
Figure 4. (a) Filter screen of expressed scFvs derived from rescued DNA
cloned from each round of CAD selection. Spiking 1:25000 of anti-phOx–
P2A DNA into (scFv)n–P2A library with diversity of n = 50 million unique
scFvs,thefractionofpositivesfromarandomselectionof3040clonesisshown.
(b) Enrichment obtained from each round of selection (total of 800-fold).
R0–R1: 50-fold; R1–R2: 8-fold; and R2–R3: 2-fold.
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enrichment), and similarly 8 clones ( 300-fold enrichment)
for the 1:10
5 spiking (data not shown). On studying the results
above, where the ratio of scFv–PLA spiked with other irrel-
evant scFv–PLA DNA molecules is l:25000, the likelihood
that the correct scFv is randomly chosen, is very low. The
probability of selecting 82 positive clones from a random
sample of 3040 candidates with a population of 5 · 10
7
and having 1 positive among 25000 clone is as low as
10
 13 [P, N(0,1)]. This argues strongly that the one given
molecule of P2A should bind to its own molecule of DNA
that directed its synthesis.
The translation complex formed among DNA, mRNA, ribo-
somesandproteins iscommon inprokaryotes. This implies the
production of extra mRNAs and an overexpression of the P2A
protein. Liu and Hagga ˚rd-Ljungquist (15) describe the inab-
ility to complement an amber A mutant by the overexpression
of normal A protein on a second plasmid. This indicates high-
ﬁdelity cis-activity. The authors suggest either compartmen-
talization of ‘A’ protein or rapid inactivation of A as the
mechanism for controlling cis-activity. It may be that the
strong cis-effect is due to the coupling of P2A with single-
stranded DNA that is available only during the melting of
double-stranded DNA with RNA polymerase, and that other
free P2A proteins may be inactive for nicking. P2A cannot
bind to double-stranded DNA (15), and thus, free scFv–P2A
molecules should not be able to bind to untranscribed double-
stranded DNA. It is also possible to purify P2A without cova-
lently bound DNA, suggesting that P2A can be released from
the ribosome without binding to DNA. The experiments, how-
ever, demonstrate a speciﬁc recovery of protein–DNA com-
plexes. The downward trend during selections (Figure 4) may
be explained wherein, for each round of selection, more active
scFv–P2A fusion proteins are formed. It is most likely that the
majority of these protein complexes were not bound to DNA.
However, this does not inﬂuence the cis-activity since only
single-stranded DNA is nicked by P2A. On the other hand, it
affected the panning. The free, uncomplexed scFv–P2A fusion
proteins compete with the corresponding DNA–protein com-
plexes. Thus, the more the concentration of scFv–P2A protein
fusions is increased, the less the DNA–protein complexes are
isolated. Panning a more complex library (e.g. n = 10
14)
should not however involve this type of problem since the
initial concentration of expressed active proteins is very
low and should not compete with DNA–protein complexes.
This was also seen from the spiking experiments. Starting with
a more diverse library (1:10
5), the initial enrichment from
R0 to R1 was larger (300-fold) compared to less diverse
spikings 1:2.5 · 10
3 and 1:10
3 that only had 50- and
14-fold enrichments, respectively. The CAD method has to
be developed further to deal with these technical problems,
which probably only arise at the ﬁnal enrichment cycles.
It may be possible to ﬁrst purify all DNA before selection
on protein complexes. The initial isolation of DNA could
be performed with biotinylated DNA and SA-beads before
subjecting it to an ordinary panning against active protein.
Panning tetanus toxoid scFvs from a 5   10
7 library
The human antibody library, (scFv)n–P2A, was also selected
against tetanus toxoid (TTx). The serum antibody titre of the
donor against TTx was found to be about 1:25000, implying
that it should be possible to identify anti-TTx scFv antibodies
derived from donor lymphocytes. For each round of selection
against TTx, 10 mg of DNA of the (scFv)n–P2A library was
applied as an input for coupled transcription and translation.
Indeed, as shown in Figure 5, after one round (R1) of CAD
several anti-TTx scFvs were identiﬁed by ELISA. The total
yield of available anti-TTx–P2A DNA after each round of
selection was estimated from anti-phOx–P2A DNA standards
at known concentrations (pg range). The input DNA was
correlated with the corresponding PCR yields of anti-TTx
scFv DNA versus anti-phOx DNA standards on an agarose
gel. After the ﬁrst round of selection (R1), the amount of
input DNA for PCR (recovered DNA) was  0.2 pg, which
equals a DNA recovered/input ratio of 1/50000000. After two
and three rounds of selection (R2 and R3), the estimated ratio
increased to 1/2500000 and 1/420000, respectively. The
CAD-enriched library was also analysed by ﬁlter screen
with no scFvs isolated before selection (background, 3040
colonies screened). However, after R1 of CAD, the number
of positives increased to 26 (26/3040). Most of these clones
bound BSA (TTx-5, Figure 5). Nevertheless, some anti-TTx
scFvs not cross-reacting with BSA were conﬁrmed by ELISA.
After R2 and R3, other scFvs were rescued and TTx-12
isolated after two rounds of CAD was speciﬁc for TTx.
Clones were also analysed by RFLP. The R1 clones were
unique. However, TTx-8 and TTx-12 (both R2 clones) had
identical RLFP patterns and DNA sequence (Table 1). The
same HCDR3 sequence also appeared for TTx-17 (R3 clone),
although there was a difference in their LCDR3 region (Table
1), suggesting a sequence enrichment during R1–R3 of CAD.
Furthermore, the HCDR3 sequences in this study were aligned
with known human anti-TTx antibody sequences [Table 1 and
(31,32)]. The residues at the C-terminal region of HCDR3 of
TTx-12/TTx-17 (R2/R3 clones, respectively) were very sim-
ilar to 6-ATT (33), suggesting a selection on the same epitope
of TTx. Similarly, most of the HCDR3 sequences compared in
Table 1 have a positively charged N-terminal (at position
105 or 106) and an Asp residue at position 116. For the
Figure 5. PanninganscFvlibrary.(scFv)n–P2A(n=50millionuniqueclones)
against tetanus toxoid. ELISA of R1 of CAD. A total of 92 clones were
randomly picked and assayed (ELISA). Only clones with A450 > 0.15 are
shown (anti-TTx scFv, closed bar; BSA, open bar).
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CAD as a new in vitro antibody display tool
We have demonstrated the successful selections from two
independent spiking experiments (phOx and DOB fusions)
and from an immunized scFv library with a complexity of
10
7. The method should thus be well suited for in vitro
scFv selections from libraries. However, in order to fully dem-
onstrate its potential, a more diverse library should be
screened. P2A can be applied as a general panning tool for
antibody library selections at the N-terminal end of the endo-
nuclease. The advantages for such a selection system are
numerous, compared to the existing phage display and in vitro
mRNA display methods. CAD is the only antibody selection
method providing a direct covalent link between an scFv gene
and its protein (14–16), increasing the chemical stability of the
panning complex. Table 2 compares the more common meth-
ods of in vitro selection, and all methods have their advantages
and disadvantages. The new DNA-based cis-display methods
of panning are however very promising. Generally, CAD may
facilitate a very rapid library generation using PCR methods
with increased library complexity size (potentially up to 10
13
scFv members) and a fast cycle time. In a few hours, unique
scFvs can be enriched, isolated and directly ampliﬁed for the
next rounds of selection (Figure 1c). The system should be
very well suited for scaling up and automation, and may be a
future standard for in vitro antibody selections. However, at
present, the CAD methods must be made more robust to over-
come the product inhibition of uncomplexed fusion proteins
without DNA. CAD offers a covalent antibody selection tool
as an alternative to the latest non-covalent in vitro display
selection method of peptides and proteins with the RepA
protein (36).
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